Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Eurofins Ntd Llc |
RCV000176855 | SCV000228611 | likely pathogenic | not provided | 2015-04-22 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV000176855 | SCV001575410 | likely pathogenic | not provided | 2023-02-13 | criteria provided, single submitter | clinical testing | Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt COL2A1 protein function. This variant disrupts the triple helix domain of COL2A1. Glycine residues within the Gly-Xaa-Yaa repeats of the triple helix domain are required for the structure and stability of fibrillar collagens (PMID: 7695699, 8218237, 19344236). In COL2A1, variants affecting these glycine residues are significantly enriched in individuals with disease (PMID: 9016532, 17078022) compared to the general population (ExAC). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. ClinVar contains an entry for this variant (Variation ID: 196112). This sequence change replaces glycine, which is neutral and non-polar, with arginine, which is basic and polar, at codon 621 of the COL2A1 protein (p.Gly621Arg). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with COL2A1-related conditions. |
| Blueprint Genetics | RCV000176855 | SCV001832331 | likely pathogenic | not provided | 2019-11-30 | criteria provided, single submitter | clinical testing |